{
  "ticker": "REPL",
  "company_name": "Replimune Group, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06898970",
      "title": "Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Angiosarcoma, Angiosarcoma, Adult",
      "start_date": "2026-01-30",
      "completion_date": "2029-10-31",
      "enrollment": 0,
      "sponsor": "Varun Monga, MBBS"
    },
    {
      "nct_id": "NCT04336241",
      "title": "Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Cancer",
      "start_date": "2019-10-17",
      "completion_date": "2028-04-30",
      "enrollment": 0,
      "sponsor": "Replimune Inc."
    },
    {
      "nct_id": "NCT03767348",
      "title": "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma",
      "start_date": "2017-09-20",
      "completion_date": "2028-12",
      "enrollment": 0,
      "sponsor": "Replimune Inc."
    },
    {
      "nct_id": "NCT05733611",
      "title": "RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Refractory Metastatic Colorectal Cancer, pMMR, MSS",
      "start_date": "2023-06-29",
      "completion_date": "2027-03-01",
      "enrollment": 0,
      "sponsor": "Replimune Inc."
    },
    {
      "nct_id": "NCT04050436",
      "title": "Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma",
      "start_date": "2019-10-08",
      "completion_date": "2025-09",
      "enrollment": 0,
      "sponsor": "Replimune Inc."
    },
    {
      "nct_id": "NCT06887348",
      "title": "A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3",
      "status": "RECRUITING",
      "phase": "",
      "condition": "Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma",
      "start_date": "2025-12-12",
      "completion_date": "2035-12",
      "enrollment": 0,
      "sponsor": "Replimune Inc."
    },
    {
      "nct_id": "NCT06623110",
      "title": "Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "High-Risk Oral Precancerous Disease",
      "start_date": "2025-01-01",
      "completion_date": "2029-01-01",
      "enrollment": 0,
      "sponsor": "Glenn J. Hanna"
    },
    {
      "nct_id": "NCT05733598",
      "title": "Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Hepatocellular Carcinoma, Biliary Tract Cancer",
      "start_date": "2024-08-01",
      "completion_date": "2028-07-01",
      "enrollment": 0,
      "sponsor": "Replimune Inc."
    },
    {
      "nct_id": "NCT06590480",
      "title": "An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma",
      "status": "NO_LONGER_AVAILABLE",
      "phase": "",
      "condition": "Advanced Melanoma",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Replimune Inc."
    },
    {
      "nct_id": "NCT06216938",
      "title": "RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis",
      "status": "RECRUITING",
      "phase": "EARLY_PHASE1",
      "condition": "Melanoma",
      "start_date": "2024-03-07",
      "completion_date": "2027-03-31",
      "enrollment": 0,
      "sponsor": "Yana Najjar"
    }
  ],
  "summary": {
    "total_trials": 17,
    "by_phase": {
      "PHASE2": 8,
      "PHASE1": 2,
      "": 2,
      "EARLY_PHASE1": 1,
      "PHASE1, PHASE2": 2,
      "PHASE3": 1,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "RECRUITING": 9,
      "ACTIVE_NOT_RECRUITING": 4,
      "NO_LONGER_AVAILABLE": 1,
      "NOT_YET_RECRUITING": 1,
      "WITHDRAWN": 1,
      "TERMINATED": 1
    },
    "active_trials": 13,
    "completed_trials": 0,
    "conditions": [
      "Advanced Melanoma",
      "Advanced Solid Tumor",
      "Angiosarcoma, Angiosarcoma, Adult",
      "Cancer",
      "Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma",
      "Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Melanoma",
      "Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma",
      "Hepatocellular Carcinoma, Biliary Tract Cancer",
      "High-Risk Oral Precancerous Disease",
      "Melanoma",
      "Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma",
      "Metastatic Uveal Melanoma",
      "Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma",
      "Refractory Metastatic Colorectal Cancer, pMMR, MSS",
      "Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma",
      "Triple Negative Breast Neoplasms"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:21:27.812281",
    "search_query": "Replimune Group, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Replimune+Group,+Inc."
  }
}